Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immune Network nears patent for HIV antibody:

This article was originally published in Clinica

Executive Summary

Canada's Immune Network has received a notice of allowance on two US patents related to its 1F7 technology for HIV diagnosis and treatment. The patents, when issued, will cover the Vancouver, British Columbia firm's anti-idiotypic antibody and its use in diagnosis and therapy in HIV-related diseases. Immune Network recently announced that biopharmaceutical firm AbNovo had acquired a licence option on the 1F7 technology as well as on the company's anti-HIV monoclonal antibody, hNM01.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT068059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel